Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer.

Garrido MF, Martin NJ, Bertrand M, Gaudin C, Commo F, El Kalaany N, Al Nakouzi N, Fazli L, Del Nery E, Camonis J, Perez F, Lerondel S, Le Pape A, Compagno D, Gleave M, Loriot Y, Désaubry L, Vagner S, Fizazi K, Chauchereau A.

Clin Cancer Res. 2019 Jan 15;25(2):710-723. doi: 10.1158/1078-0432.CCR-18-0704. Epub 2018 Oct 15.

PMID:
30322877
2.

Compound Functional Prediction Using Multiple Unrelated Morphological Profiling Assays.

Rose F, Basu S, Rexhepaj E, Chauchereau A, Del Nery E, Genovesio A.

SLAS Technol. 2018 Jun;23(3):243-251. doi: 10.1177/2472630317740831. Epub 2017 Nov 3.

PMID:
29100480
3.

Stable and high expression of Galectin-8 tightly controls metastatic progression of prostate cancer.

Gentilini LD, Jaworski FM, Tiraboschi C, Pérez IG, Kotler ML, Chauchereau A, Laderach DJ, Compagno D.

Oncotarget. 2017 Jul 4;8(27):44654-44668. doi: 10.18632/oncotarget.17963.

4.

A new model of multi-visceral and bone metastatic prostate cancer with perivascular niche targeting by a novel endothelial specific adenoviral vector.

Lu ZH, Kaliberov S, Sohn RE, Kaliberova L, Du Y, Prior JL, Leib DJ, Chauchereau A, Sehn JK, Curiel DT, Arbeit JM.

Oncotarget. 2017 Feb 14;8(7):12272-12289. doi: 10.18632/oncotarget.14699.

5.

Functional Assessment of Genetic Variants with Outcomes Adapted to Clinical Decision-Making.

Thouvenot P, Ben Yamin B, Fourrière L, Lescure A, Boudier T, Del Nery E, Chauchereau A, Goldgar DE, Houdayer C, Stoppa-Lyonnet D, Nicolas A, Millot GA.

PLoS Genet. 2016 Jun 6;12(6):e1006096. doi: 10.1371/journal.pgen.1006096. eCollection 2016 Jun.

6.

Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis.

Al Nakouzi N, Wang CK, Beraldi E, Jager W, Ettinger S, Fazli L, Nappi L, Bishop J, Zhang F, Chauchereau A, Loriot Y, Gleave M.

EMBO Mol Med. 2016 Jul 1;8(7):761-78. doi: 10.15252/emmm.201506059. Print 2016 Jul.

7.

Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer.

Al Nakouzi N, Cotteret S, Commo F, Gaudin C, Rajpar S, Dessen P, Vielh P, Fizazi K, Chauchereau A.

Oncotarget. 2014 Feb 15;5(3):667-78.

8.

A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease.

Laderach DJ, Gentilini LD, Giribaldi L, Delgado VC, Nugnes L, Croci DO, Al Nakouzi N, Sacca P, Casas G, Mazza O, Shipp MA, Vazquez E, Chauchereau A, Kutok JL, Rodig SJ, Elola MT, Compagno D, Rabinovich GA.

Cancer Res. 2013 Jan 1;73(1):86-96. doi: 10.1158/0008-5472.CAN-12-1260. Epub 2012 Oct 29.

9.

The IGR-CaP1 xenograft model recapitulates mixed osteolytic/blastic bone lesions observed in metastatic prostate cancer.

Al Nakouzi N, Bawa O, Le Pape A, Lerondel S, Gaudin C, Opolon P, Gonin P, Fizazi K, Chauchereau A.

Neoplasia. 2012 May;14(5):376-87.

10.

Experimental models for the development of new medical treatments in prostate cancer.

Chauchereau A.

Eur J Cancer. 2011 Sep;47 Suppl 3:S200-14. doi: 10.1016/S0959-8049(11)70166-6. Review. No abstract available.

PMID:
21943976
11.

A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas.

Farace F, Massard C, Vimond N, Drusch F, Jacques N, Billiot F, Laplanche A, Chauchereau A, Lacroix L, Planchard D, Le Moulec S, André F, Fizazi K, Soria JC, Vielh P.

Br J Cancer. 2011 Sep 6;105(6):847-53. doi: 10.1038/bjc.2011.294. Epub 2011 Aug 9.

12.

Ligand-dependent degradation of SRC-1 is pivotal for progesterone receptor transcriptional activity.

Amazit L, Roseau A, Khan JA, Chauchereau A, Tyagi RK, Loosfelt H, Leclerc P, Lombès M, Guiochon-Mantel A.

Mol Endocrinol. 2011 Mar;25(3):394-408. doi: 10.1210/me.2010-0458. Epub 2011 Jan 27.

13.

Bioresponsive hyperbranched polymers for siRNA and miRNA delivery.

Rahbek UL, Nielsen AF, Dong M, You Y, Chauchereau A, Oupicky D, Besenbacher F, Kjems J, Howard KA.

J Drug Target. 2010 Dec;18(10):812-20. doi: 10.3109/1061186X.2010.527982. Epub 2010 Oct 27.

PMID:
20979442
14.

Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer.

Chauchereau A, Al Nakouzi N, Gaudin C, Le Moulec S, Compagno D, Auger N, Bénard J, Opolon P, Rozet F, Validire P, Fromont G, Fizazi K.

Exp Cell Res. 2011 Feb 1;317(3):262-75. doi: 10.1016/j.yexcr.2010.10.012. Epub 2010 Oct 23.

PMID:
20974126
15.

The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer.

Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A, Chauchereau A, Fizazi K.

Eur J Cancer. 2010 Jul;46(10):1770-2. doi: 10.1016/j.ejca.2010.04.010. Epub 2010 May 17.

PMID:
20483588
16.

Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer.

Rajpar S, Massard C, Laplanche A, Tournay E, Gross-Goupil M, Loriot Y, Di Palma M, Bossi A, Escudier B, Chauchereau A, Fizazi K.

Ann Oncol. 2010 Sep;21(9):1864-9. doi: 10.1093/annonc/mdq037. Epub 2010 Feb 24.

PMID:
20181574
17.

E2F3 is a mediator of DNA damage-induced apoptosis.

Martinez LA, Goluszko E, Chen HZ, Leone G, Post S, Lozano G, Chen Z, Chauchereau A.

Mol Cell Biol. 2010 Jan;30(2):524-36. doi: 10.1128/MCB.00938-09. Epub 2009 Nov 16.

18.

The quest for the 'bony Grail' of detecting circulating tumour cells in patients with prostate cancer.

Massard C, Chauchereau A, Fizazi K.

Ann Oncol. 2009 Feb;20(2):197-9. doi: 10.1093/annonc/mdp017. No abstract available.

PMID:
19211498
19.

The postchemotherapy PSA surge syndrome.

Thuret R, Massard C, Gross-Goupil M, Escudier B, Di Palma M, Bossi A, de Crevoisier R, Chauchereau A, Fizazi K.

Ann Oncol. 2008 Jul;19(7):1308-11. doi: 10.1093/annonc/mdn062. Epub 2008 Mar 19.

PMID:
18356135
20.

Ligand-controlled interaction of histone acetyltransferase binding to ORC-1 (HBO1) with the N-terminal transactivating domain of progesterone receptor induces steroid receptor coactivator 1-dependent coactivation of transcription.

Georgiakaki M, Chabbert-Buffet N, Dasen B, Meduri G, Wenk S, Rajhi L, Amazit L, Chauchereau A, Burger CW, Blok LJ, Milgrom E, Lombès M, Guiochon-Mantel A, Loosfelt H.

Mol Endocrinol. 2006 Sep;20(9):2122-40. Epub 2006 Apr 27.

PMID:
16645042
21.

Involvement of {beta}-catenin and unusual behavior of CBP and p300 in glucocorticosteroid signaling in Schwann cells.

Fonte C, Grenier J, Trousson A, Chauchereau A, Lahuna O, Baulieu EE, Schumacher M, Massaad C.

Proc Natl Acad Sci U S A. 2005 Oct 4;102(40):14260-5. Epub 2005 Sep 26.

22.

Differential recruitment of p160 coactivators by glucocorticoid receptor between Schwann cells and astrocytes.

Grenier J, Trousson A, Chauchereau A, Cartaud J, Schumacher M, Massaad C.

Mol Endocrinol. 2006 Feb;20(2):254-67. Epub 2005 Sep 22.

PMID:
16179382
23.

Effects of FSH and 17beta-estradiol on the transactivation of estrogen-regulated promoters and cell proliferation in L cells.

Pasapera AM, Jiménez-Aguilera Mdel P, Chauchereau A, Milgrom E, Olivares A, Uribe A, Gutiérrez-Sagal R, Ulloa-Aguirre A.

J Steroid Biochem Mol Biol. 2005 Mar;94(4):289-302. Epub 2005 Feb 12.

PMID:
15857748
24.

HDAC4 mediates transcriptional repression by the acute promyelocytic leukaemia-associated protein PLZF.

Chauchereau A, Mathieu M, de Saintignon J, Ferreira R, Pritchard LL, Mishal Z, Dejean A, Harel-Bellan A.

Oncogene. 2004 Nov 18;23(54):8777-84.

PMID:
15467736
25.

Selective recruitment of p160 coactivators on glucocorticoid-regulated promoters in Schwann cells.

Grenier J, Trousson A, Chauchereau A, Amazit L, Lamirand A, Leclerc P, Guiochon-Mantel A, Schumacher M, Massaad C.

Mol Endocrinol. 2004 Dec;18(12):2866-79. Epub 2004 Aug 26.

PMID:
15331759
26.

Subcellular localization and mechanisms of nucleocytoplasmic trafficking of steroid receptor coactivator-1.

Amazit L, Alj Y, Tyagi RK, Chauchereau A, Loosfelt H, Pichon C, Pantel J, Foulon-Guinchard E, Leclerc P, Milgrom E, Guiochon-Mantel A.

J Biol Chem. 2003 Aug 22;278(34):32195-203. Epub 2003 Jun 4.

27.

Sumoylation of the progesterone receptor and of the steroid receptor coactivator SRC-1.

Chauchereau A, Amazit L, Quesne M, Guiochon-Mantel A, Milgrom E.

J Biol Chem. 2003 Apr 4;278(14):12335-43. Epub 2003 Jan 14.

28.

JAB1 interacts with both the progesterone receptor and SRC-1.

Chauchereau A, Georgiakaki M, Perrin-Wolff M, Milgrom E, Loosfelt H.

J Biol Chem. 2000 Mar 24;275(12):8540-8.

29.

Interplay between estrogens, progestins, retinoic acid and AP-1 on a single regulatory site in the progesterone receptor gene.

Savouret JF, Rauch M, Redeuilh G, Sar S, Chauchereau A, Woodruff K, Parker MG, Milgrom E.

J Biol Chem. 1994 Nov 18;269(46):28955-62.

30.

Phosphorylation sites in ligand-induced and ligand-independent activation of the progesterone receptor.

Chauchereau A, Cohen-Solal K, Jolivet A, Bailly A, Milgrom E.

Biochemistry. 1994 Nov 15;33(45):13295-303.

PMID:
7947737
31.

The progesterone receptor. Biological effects of progestins and antiprogestins.

Savouret JF, Chauchereau A, Misrahi M, Lescop P, Mantel A, Bailly A, Milgrom E.

Hum Reprod. 1994 Jun;9 Suppl 1:7-11. Review.

PMID:
7962473
32.

Mechanisms controlling the cellular traffic and the concentration of the progesterone receptor.

Savouret JF, Perrot-Applanat M, Lescop P, Guiochon-Mantel A, Chauchereau A, Milgrom E.

Ann N Y Acad Sci. 1993 Jun 11;684:11-8. Review. No abstract available.

PMID:
8317823
33.

Control of biosynthesis and post-transcriptional modification of the progesterone receptor.

Chauchereau A, Savouret JF, Milgrom E.

Biol Reprod. 1992 Feb;46(2):174-7. Review.

PMID:
1536892
34.

[Molecular biology of the hormonal receptors in the genital tract].

Chauchereau A, Loosfelt H, Misrahi M, Mantel A, Lescop P, Atger M, Ghinea N, Vu Hai M, Milgrom E.

J Gynecol Obstet Biol Reprod (Paris). 1992;21(3):292. French. No abstract available.

PMID:
1351070
35.

Phosphorylation of transfected wild type and mutated progesterone receptors.

Chauchereau A, Loosfelt H, Milgrom E.

J Biol Chem. 1991 Sep 25;266(27):18280-6.

36.

Characterization of the hormone responsive element involved in the regulation of the progesterone receptor gene.

Savouret JF, Bailly A, Misrahi M, Rauch C, Redeuilh G, Chauchereau A, Milgrom E.

EMBO J. 1991 Jul;10(7):1875-83.

37.

Co-operation of progestational steroids with epidermal growth factor in activation of gene expression in mammary tumor cells.

Krusekopf S, Chauchereau A, Milgrom E, Henderson D, Cato AC.

J Steroid Biochem Mol Biol. 1991;40(1-3):239-45.

PMID:
1958527
38.

Progress in the study of receptors involved in steroidogenesis and steroid hormone action.

Chauchereau A, Loosfelt H, Misrahi M, Atger M, Guiochon-Mantel A, Lescop P, Perrot-Applanat M, Milgrom E.

J Steroid Biochem Mol Biol. 1991;40(1-3):21-3. Review. No abstract available.

PMID:
1958523
39.

Automation of a chloramphenicol acetyltransferase assay.

Chauchereau A, Astinotti D, Bouton MM.

Anal Biochem. 1990 Aug 1;188(2):310-6.

PMID:
2221379

Supplemental Content

Loading ...
Support Center